Fludarabine
Tumor Infiltrating Lymphocytes
Shanghai Juncell TherapeuticsSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Tumor Infiltrating Lymphocytes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gc101 Shanghai Juncell Therapeutics | Phase 1/2 | B |
pd1-til Ruijin Hospital | Phase 1 | CC |
pd-1 knockout engineered t cells Ruijin Hospital | Phase 1 | CC |
Cyclophosphamide Shanghai Juncell Therapeutics | Early Phase 1 | C |
TIL Shanghai Juncell Therapeutics | Early Phase 1 | C |
gc203 til Shanghai Juncell Therapeutics | Early Phase 1 | C |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →